



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>4</sup> :</b>  <b>B08B 11/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 87/ 04091</b>  <b>(43) International Publication Date:</b> 16 July 1987 (16.07.87)
<b>(21) International Application Number:</b> PCT/US87/00045 <b>(22) International Filing Date:</b> 5 January 1987 (05.01.87)  <b>(31) Priority Application Number:</b> 816,518 <b>(32) Priority Date:</b> 6 January 1986 (06.01.86) <b>(33) Priority Country:</b> US  <b>(71) Applicant:</b> ALLERGAN, INC. [US/US]; 2525 Dupont Drive, Irvine, CA 92715 (US).  <b>(72) Inventors:</b> HUTH, Stanley, W. ; 725 Baywood Drive, Newport Beach, CA 92660 (US). LAM, Sam, W. ; 3 Shaddock, Irvine, CA 92720 (US).  <b>(74) Agents:</b> KANAGY, James, M.; Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92715 (US) et al.		<b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> ENHANCEMENT OF ENZYMATIC ACTIVITY IN CLEANING CONTACT LENSES BY THE USE OF HYPOTONIC SOLUTIONS		
<b>(57) Abstract</b>  <p>Hypotonic solutions enhance enzymatic activity in proteolytic cleaning of contact lenses. The hypotonic solution may have an osmolality value ranging between 0 and 275 mOsm/kg, but preferably will be between 100 and 200 mOsm/kg.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

1

-1-

5

ENHANCEMENT OF ENZYMATIC ACTIVITY IN CLEANING  
CONTACT LENSES BY THE USE OF HYPOTONIC SOLUTIONS

Background

10

This invention relates to the potentiation of the enzymatic activity in cleaning contact lenses. More specifically, this invention is a method for potentiating the proteolytic activity of proteases in the cleaning of contact lenses by carrying out the cleaning in a hypotonic solution.

15

Related Art

20

Contact lenses, particularly those with a hydrophilic surface such as the hydrogel lenses and the hard, gas permeable lenses with a treated surface, encounter protein accretions during normal wear. It is beneficial, if not often times necessary, to remove these accretions in order to maintain visual acuity, prevent eye irritation and to prevent the development of giant papillary conjunctivitis.

25

The use of proteolytic enzymes has been developed to remove such deposits. See, for example, U.S. Patent 3,910,296, and 4,285,738. The '296 disclosure makes no comment on the effect of tonicity value on enzyme activity. The '738 patent discloses in the specification and stipulates in the claim, that the solution must be hypertonic. Hypertonic is not specifically defined, but the urea concentration is specified as being between 5% through saturation (weight/volume). The normal tonicity

30

35

-2-

1 value is that of a physiological solution as illustrated  
by the 0.9% by weight/volume concentration of aqueous  
saline.

5 It has now been found that where the enzymatic  
solution is made hypotonic, removal of adhered protein by  
the enzyme is substantially enhanced throughout the  
effective pH range of the enzyme. Studies were carried  
out with several enzymes, papain, subtilisin, pancreatin,  
each of which clearly demonstrated a substantial increase  
in activity when the solution was made hypotonic.

10

#### Summary of the Invention

15 This invention covers a method for enhancing the  
activity of an enzyme used in the cleaning of contact  
lenses, which method comprises carrying out the cleaning  
regime in a solution having an osmolality value up to  
about 275 milliosmoles/kilogram.

#### Specific Embodiments

20 The use of a hypotonic solution to enhance enzyme  
activity for cleaning contact lenses is applicable to any  
proteolytic enzyme which may be used to remove protein  
from contact lenses.

25 Tonicity values may range from 0 up to about 275  
mOsm/kg. The enzyme itself will be active at tonicity  
values close to 0, but as a practical matter it is  
difficult to prepare such solutions because of the solutes  
normally present in diluents, including purified water.  
Tests have been carried out where the osmolality was as  
low as 6 mOsm/kg. A more preferred lower limit is about  
30 50 mOsm/kg, which number allows for the addition of small  
amounts of salts, stabilizers, enzyme co-factors or other  
excipients which may be useful and beneficial to solution  
stability, enzyme activity or the like.

35 On the upper side, 275 milliosmoles is approximately

-3-

1 the top end of the range so far as enjoying substantially  
enhanced proteolytic activity is concerned. More  
preferably, the upper limit will be between 175 and 200  
mOsm/kg.

5 The adjustment of tonicity value can be made with any  
number of excipients and constituents well known in the  
art. If an enzyme co-factor is critical or essential to  
the cleaning process, obviously its presence must be given  
primary consideration in adding materials to the  
10 formulation. Salts of any sort including salts which are  
necessary co-factors for enzymatic activity such as  
calcium should be accounted for in formulating these  
hypotonic solutions. The hypotonic value is determined,  
that is measured, after addition of the enzyme.

15 In the following examples, the ability of a given  
solution and enzyme to remove protein from a contact lens  
was determined by essentially the same procedure each  
time. Generically, the procedure was to take a contact  
lens and coat it with heat denatured lysozyme by placing  
20 the lens in a phosphate buffered saline solution to which  
was then added sufficient lysozyme to make a 0.1% solution  
by weight. The lysozyme was from egg white. These  
solutions were then heated for 30 minutes at about 95 C.  
The lenses were removed, cooled and rinsed with distilled  
25 water and viewed to determine what type of lysozyme  
accretion was on the lens at time zero.

Protein deposit classification (typing): as a means  
for quantifying the proteolytic activity of enzymes in  
removing absorbed protein from the lenses, a system was  
developed whereby the protein on the lenses was visually  
30 quantified before and after enzyme treatment.

After a lens had been heated for 30 minutes in the  
lysozyme solution, the lens was wetted with distilled  
water, rubbed between the thumb and finger, then grasped  
by the edge with plastic tweezers and rinsed with  
35

-4-

1 distilled water again. The convex side of the lens was  
viewed under a microscope at 100X magnification. A film  
or deposit detected under these conditions was classified  
according to the percentage of the lens surface covered by  
the deposit. The protein removal efficacy of an enzyme  
5 solution is expressed in terms of the percentage of the  
lens surface which has been cleaned. This number is  
derived by subtracting the percentage of the lens surface  
covered by the protein deposit from 100%.

10

Example 1Effect of Osmolality

Twenty-four Hydrocurve® II hydrogel lenses  
(Barnes-Hind, Inc. Sunnyvale, California) were coated with  
lysozyme using the standard procedure. Each was viewed  
15 after treatment and determined to have at least 98% of its  
surface covered by a protein film. In most cases, 100% of  
the lens surface was covered by a protein film. A  
subtilisin enzyme containing solution was prepared as  
follows: cysteine hydrochloride monohydrate (1.001g),  
20 sodium borate dihydrate (1.911 g), sodium carbonate  
anhydrous (3.106g), polyethylene glycol 3350 (0.403g),  
tartaric acid (2.002g), S. carlsberg (0.041g), obtained  
from Novo Industries of Denmark, was dissolved in 300 ml  
of purified water, the pH adjusted to 8.4 with sodium  
25 hydroxide or hydrochloric acid, and then water added in a  
quantity sufficient to make 1000 ml. Three 200 ml  
portions were removed and the osmolality adjusted with  
sodium chloride and the pH with NaOH or HCl as needed to  
obtain the figures given in table I.

30 Three lenses were soaked in each of the solutions for  
3 hours at room temperature, then a determination of  
percentage residual protein deposit and cleaned lens  
surface made as per the standard procedure described  
above.

35

TABLE I - Effect of Osmolality  
Average % Lens Surface Cleaned

	<u>pH</u>			
	9	98.3±2.9	23.3±5.8	11.7±5.8
	8.5	100	11.7±2.9	13.3±2.9
5	7.8	90±17	-----	3.3±2.9
		150	326	420
		Osmolality (mOsm/kg)		

10 Table I shows that greater cleaning was observed at 150 mOsm/kg than at either 326 or 420 mOsm/kg.

Example 2

Effect of pH vs. Osmolality

15 Hydrogel-type lenses (Hydrocurve II<sup>®</sup>, 55% water, sold by Barnes-Hind, Inc.) were treated with heat-denatured lysozyme as described above.

20 A subtilisin-A-containing solution was prepared (0.04 mg/ml of water without excipients, activity: 0.0012 Au/ml) in such a manner as to have pH values between approximately 5.0 and 10.0. The osmolality value was then adjusted to 6, 133 and 264 mOsm/kg with NaCl for each of these solutions, each of the tonicity values being tested at pH 9.0. Lenses were then soaked in these solutions  
 25 (five in each) for 2 hours at room temperature, rinsed, and analyzed for percentage residual protein deposit as described above. Results are given in Table II.

30

-6-

Table II - Effect of pH vs. Osmolality

		<u>% Lens Surface Cleaned</u>		
		<u>pH</u>		
	10.0	93.0 $\pm$ 4.5		
	9.0	69.0 $\pm$ 8.2	34.0 $\pm$ 5.5	18.0 $\pm$ 2.7
5	8.0	62.0 $\pm$ 4.5		
	7.0	58.0 $\pm$ 4.5		
	6.0	23.8 $\pm$ 4.8*		
	5.0	11.0 $\pm$ 2.2		
<hr/>				
10		6	133	264
		Osmolality (mOsm/kg)		

\* Only four lenses.

15 It can be seen from the data presented in Table II that both solution pH and osmolality are important parameters asserting the cleaning efficacy of an enzyme solution. Since subtilisin-A is an alkaline protease, having its greatest activity between pH 8 and 10, the greatest

20 cleaning efficacy is observed in this pH range also.

### Example 3

Lenses with lysozyme protein deposits covering at least 98% of the lens surface were cut in half, one half being soaked in one enzyme solution and the other in another enzyme solution in the first comparison (pancreatin data); whole lenses were used in the other

25 studies. The enzyme solutions were comprised of enzyme and excipients as indicated in Table III. Lenses were bafilcon-A sold by Barnes-Hind, Inc. under the name

30 Hydrocurve II $\oplus$ . Results from each of the several formulations are listed in the following table. The abbreviation DI is used for deionized water.



-7-

Table IIIEffect of Varying Osmolality on Enzyme Cleaning Efficacy

<u>Enzyme Used</u>	<u>Diluent</u>	<u>pH</u>	<u>Osmol- ality</u>	<u>Soak Time</u>	<u>Average &amp; Cleaning</u>
Pancreatin <sup>1</sup>	DI water	8.58	175	4 hrs	32.0±25.4
Pancreatin	saline <sup>2</sup>	7.97	382	4 hrs	1.3±2.3
<u>Subtilisin</u>					
<u>carlsberg</u>	DI water	8.43	157	3 hrs	98.3±2.9
0.04 mg/ml <sup>3</sup>	water & NaCl	8.43	335	3 hrs	25.6±13.9
<u>Subtilisin</u>					
<u>carlsberg</u>	DI water	8.86	124	1 hr	79.6±11.3
0.04mg/ml <sup>4</sup>	saline <sup>5</sup>	8.21	418	2 hrs	16.4±4.6

- 
1. Alcon Optizyme™ tablet.
  2. Normal saline.
  3. Same formulation excipients as in Example 1, Table I.
  4. A subtilisin enzyme tablet was dissolved in either 10ml of DI water or saline. Each enzyme tablet contained: 30mg N-acetylcysteine, 34mg sodium carbonate, 7mg tartaric acid, 4mg polyethylene glycol 3350, 4mg subtilisin-A (subtilisin carlsberg from NOVO Industries of Denmark), and 50mg of lactose.
  5. Allergan Hydrocare™ Preserved Saline.

It can be seen from the data presented in Table III that for both pancreatin and Subtilisin carlsberg, the solutions with the lowest tonicity produced the highest cleaning efficacy.

Example 4

1

The effect of osmolality values on cleaning efficacy was investigated with papain enzyme. Solutions of 1mg/ml papain, 1mg/ml L-cysteine and 0.8mg/ml EDTA at 95mOsm/kg, 193mOsm/kg and 291mOsm/kg were tested (pH 8.4). Hydrocurve II lenses (55% H<sub>2</sub>O) from Barnes-Hind were coated with denatured lysozyme as described in Example 1. Three lenses were soaked in the 95mOsm/kg solution and four lenses in each of the other two solutions. Soaking time was 3.5 hours. Total percent surface cleaned was determined as per Example 1. the results are given in Table IV.

5

10

Table IV

15

<u>Lens</u>	<u>%Surface Cleaned</u>	<u>Mean + S.D.</u>	<u>Exp. Conditions</u>
A1	100	78 <sub>±</sub> 38	1mg/ml papain, 1mg/ml L-cysteine .8mg/ml EDTA pH <sub>f</sub> =8.4 osmolality=95mOsm/1kg
A2	35		
A3	100		
B1	60	48 <sub>±</sub> 28	Same as above except osmolality = 193mOsm/1kg
B2	30		
B3	80		
B4	20		
C1	30	21 <sub>±</sub> 12	Same as above except osmolality = 291mOsm/1kg
C2	20		
C3	5		
C4	30		

20

25

30

It can be seen from the data presented in Table IV that cleaning efficacy increases with lower solution tonicity for papain-containing solutions.

35

## WHAT IS CLAIMED IS:

1

1. A method for enhancing the activity of an enzyme used in the cleaning of contact lenses, which method comprises carrying out the cleaning regimen in a solution having an osmolality value up to 275 mOsm/kg.

5

2. The method of claim 1 wherein the osmolality is between 100 and 200 mOsm/kg.

10

15

20

25

30

35

# INTERNATIONAL SEARCH REPORT

International Application No PCT/US87/00045

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>3</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
INT. CL. <sup>4</sup> B08B 11/00		
US CL. 134/25.1		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>4</sup>		
Classification System	Classification Symbols	
US	134/25.1, 25.4, 26, 28, 42 252/DIG. 12, 105, 174.12, 525 435/262, 264	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>5</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT</b> <sup>14</sup>		
Category *	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No. <sup>18</sup>
Y	US, A, 4,521, 254 (ANDERSON ET AL), PUBLISHED 04 JUNE 1985, See cols. 10-11, lines 48-68, and lines 1-5, and lines 15-21, respectively.	1, 2
Y	US, A, 3,910,296 (KARAGEOZIAN ET AL), PUBLISHED 07 OCTOBER 1975, See examples 1-4, cols. 5-6, respectively.	1, 2
Y	US, A, 4,285,738 (OGATA), PUBLISHED 25 AUGUST 1981, See col. 2, lines 7-13.	1, 2
A	US, A, 3,240,709 (RANKIN), PUBLISHED 15 MARCH 1966, See col. 1, lines 13-17, and lines 59-61, respectively.	1, 2
A	US, A, 4,048,122 (SIBLEY ET AL), PUBLISHED 13 SEPTEMBER 1977, See col. 1, lines 51-55.	1, 2
A	US, A, 4,613,380 (CHEN), PUBLISHED 23 SEPTEMBER 1986, See col. 1, lines 1-14.	1, 2
A	US, A, 4,263,054 (GIAMBALVO), PUBLISHED 21 APRIL 1981, See col. 1, lines 20-28.	1, 2
<p>* Special categories of cited documents: <sup>15</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search <sup>2</sup>		Date of Mailing of this International Search Report <sup>2</sup>
26 FEBRUARY 1987		06 MAR 1987
International Searching Authority <sup>1</sup>		Signature of Authorized Officer <sup>19</sup>
ISA/US		<i>Sharon T. Cohen</i> SHARON T. COHEN

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category*	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No <sup>18</sup>
A	US, A, 4,626,292 (SHERMAN), PUBLISHED 02 DECEMBER 1986, See col. 2, lines 59-65.	1, 2